Replies to post #97207 on Biotech Values

[DewDiligence]

So the [regulatory] discussion [for Ipilimumab] will about the appropriate label…

Maybe, but not necessarily. The regulatory discussion may also be about whether the FDA should insist on another trial before granting approval. You completely missed the point of this thread.